Technology

Solution to current limitations

Our technology offers to assay a comprehensive set of epigenetic markers beyond the well-known DNA methylation and thus is a timely solution to the current limitations in the field. Through a highly multiplexed and quantitative assay design, Epigenica can offer high-throughput profiling of epigenetic on-target and off-target effects of drugs. The technology can be widely applied to measure both immediate- and long-term epigenetic alterations after drug treatment.

epigenica - solution to current limitations

The power lies in the ability to include a large set of markers into a global analysis and retain the ability to focus on specific genomic regions in the same analysis. Our breakthrough in epigenetic profiling provides a framework for high-throughput, low-cost elucidation of short- and long-term action and toxicology of epigenetic drugs, or any drug candidate that could affect epigenetic markers as a target or side effect. Our technology allows for the early and comprehensive screening of epigenetic (side) effects of drug candidates to predict efficacy and toxicology in an early stage of cell-based characterization and thus reduce the costs, increase the efficacy and accelerate the process in drug discovery pipelines.

"Our technology allows drug developers to identify and optimize the best leads, save costs through more comprehensive early characterization and avoid expensive failures in later phases."

Probing the epigenome in response to drugs

Drugs interact with cells in our human body in diverse ways. By design or serendipity, many drugs have effects on the epigenome. While it remains to be determined in each individual case if alterations would have a functional, potentially long-term, effect, it is relatively likely that any drug affects some global or local levels of histone PTMs or DNA modifications. This is because many common drug (side)-effects ultimately impinge on pathways that regulate the epigenome: as on or off-target, drugs may target signalling pathways that impinge on one of the many known transcription factors, proteins that, by sequence-specific binding, orchestrate epigenomic landscapes.

epigenica - probing the epigenome in response to drugs

"Our technology offers to assay a comprehensive set of epigenetic markers beyond the well-known DNA methylation and thus is a timely solution to the current limitations in the field."

epigenica - accelerating the use of epigenetics in life science

Accelerating the use of epigenetics in life science

To date, comprehensive epigenomic profiling has not been established as a part of high-throughput drug characterization, and there is a clear need for methods in this sector. Detecting epigenetic side effects in cell-based assays will be instrumental to discover adverse epigenetic side effects of drug candidates already early in the drug pipeline, thus substantially reducing the need for expensive and ethically sensitive animal experiments and clinical trials. 


Our technology allows drug developers to identify and optimize the best leads, save costs through more comprehensive early characterization and avoid expensive failures in later phases.

This website uses cookies. By continuing to use this site, you accept our use of cookies.